Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Concord Drugs Ltd has reconstituted three key Board Committees — Audit Committee, Nomination & Remuneration Committee, and Stakeholders' Relationship Committee — with effect from February 14, 2026. All three committees will now have the same three Non-Executive Independent Directors: Kasu Sumeela as Chairperson, along with S. Nagavenkata Hareesh and Satyam Reddy Gopidi as Members. The change was approved by the Board to ensure compliance with applicable statutory requirements. The disclosure was filed under SEBI's Listing Obligations and Disclosure Requirements Regulations, 2015.
This is a routine corporate governance housekeeping update with no direct impact on the company's financials or stock price. Shareholders may note that all reconstituted committees are now composed entirely of independent directors, which is a positive governance signal.